Adaptimmune Therapeutics Plc Share Price

NASDAQ: ADAP

Small Cap

$0.05

(+8.51%)

as on September 13, 2025 at 1:29 am IST

$₹

Adaptimmune Therapeutics Plc Stock Performance

as on September 13, 2025 at 1:29 am IST

Day's High
$0.05
Day's Price Range
$0.06
$0.05
20.00%
Upside
52 Week's Low
52 Week's High
$0.04
52-Week Price Range
$1.12
$0.05
19.40%
Downside
2140.00%
Upside

Adaptimmune Therapeutics Plc share price movements today

Previous Close: $0.05
Open: $0.05
Volume: 49.4M
Day's Low - High: $0.05 - $0.06
52 Week Low - High: $0.04 - $1.12

Adaptimmune Therapeutics Plc Historical Returns

1 Month Return: -5.88 %
3 Month Return: -76.89 %
1 Year Return: -94.95 %
3 Year Return: -96.54 %
5 Year Return: -99.44 %

Adaptimmune Therapeutics Plc Stock Fundamentals & Key Indicators

Check Adaptimmune Therapeutics Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$14.8M

EPS (TTM)

-0.471

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

0.11

EBITDA

-137.2M

Revenue (TTM)

65.1M

Profit Margin

-260.82%

Return On Equity TTM

93018500.00%

Adaptimmune Therapeutics Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Adaptimmune Therapeutics Plc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Adaptimmune Therapeutics Plc	BUY	$14.8M	-99.44%	NA	-260.82%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Stock Returns calculator for Adaptimmune Therapeutics Plc Stock including INR - Dollar returns

The Adaptimmune Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Adaptimmune Therapeutics Plc investment value today

Current value as on today

₹9,644

Returns

₹90,356

(-90.36%)

Returns from Adaptimmune Therapeutics Plc Stock

₹95,495 (-95.5%)

Dollar Returns*

₹5,139 (+5.14%)

Analyst Recommendation on Adaptimmune Therapeutics Plc Stock

Based on 13 analysts

BUY

69.23%

Buy

23.08%

Hold

7.69%

Sell

Based on 13 analysts, 69.23% of analysts recommend a 'BUY' rating for Adaptimmune Therapeutics Plc. Average target price of $0.68

Adaptimmune Therapeutics Plc Share Price Target

Get share price movements and forecasts by analysts on Adaptimmune Therapeutics Plc.

What analysts predicted

92.65%UPSIDE

Target Price

$0.68

Current Price

$0.05

Analyzed by

13 Analysts

Target

$0.68

Adaptimmune Therapeutics Plc target price $0.68, a slight upside of 92.65% compared to current price of $0.05. According to 13 analysts rating.

Adaptimmune Therapeutics Plc Stock's Interest Amongst Investors

Investment in Adaptimmune Therapeutics Plc Shares on INDmoney has dropped by -26.38% over the past 30 days, indicating reduced transactional activity.

Time period: August 16, 2025 to September 15, 2025

Change:-26.38% versus previous 30 day period

Search interest for Adaptimmune Therapeutics Plc Stock has increased by 48% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 16, 2025 to September 15, 2025

Change:48% versus previous 30 day period

Adaptimmune Therapeutics Plc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	47	5	7	0	5	128	40	3	7	13
Gross Profit	45	2	4	-2	2	125	40	3	6	11
Operating Income	1	-44	-46	-54	-49	68	-14	-73	-45	-30
EBITDA	-1	-20	-43	-49	-46	71	-12	-67	-42	-26
Interest Expense	0	-	-	0	-	0	1	1	1	0
Depreciation	1	2	2	2	2	2	2	2	2	2
Income Before Tax	1	-20	-44	-52	-47	67	-16	-70	-47	-29
Income Tax Expense	0	0	0	-4	0	-1	0	-1	0	0
Net Income	1	-21	-45	-48	-48	69	-17	-74	-47	-30
Net Profit Margin	2.18%	-416.94%	-623.05%	-20743.33%	-854.23%	54.22%	-43.07%	-2303.38%	-653.18%	-221.83%

Adaptimmune Therapeutics Plc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	10	14	37	59	1	3	6	27	60	178
Gross Profit	10	14	37	59	-96	-87	-104	-100	50	177
Operating Income	-23	-72	-80	-82	-139	-133	-162	-163	-138	-68
EBITDA	-23	-69	-75	-74	-131	-125	-155	-155	-128	-52
Interest Expense	0	-	2	0	2	3	4	1	-	3
Depreciation	-	-	5	7	8	7	6	6	9	11
Income Before Tax	-23	-70	-69	-95	-136	-129	-157	-162	-112	-67
Income Tax Expense	-2	0	0	0	0	0	0	2	1	3
Net Income	-21	-71	-70	-95	-137	-130	-158	-165	-113	-70
Net Profit Margin	-201.36%	-504.15%	-185.39%	-160.51%	-12225.04%	-3286.81%	-2570.99%	-609.46%	-188.90%	-39.78%

Adaptimmune Therapeutics Plc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-21	-45	-47	-48	69	-17	-70	-47	-30
Operating Cash Flow	-43	-45	-14	-31	47	-54	-34	-66	-34
Investing Cash Flow	2	57	68	0	0	-66	8	41	18
Financing Cash Flow	0	0	0	29	24	25	0	-25	1
Change in Cash	-41	12	53	-3	71	-95	-26	-50	-15

Adaptimmune Therapeutics Plc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-71	-70	-95	-137	-130	-158	-165	-113	-70
Operating Cash Flow	-48	-54	-104	-112	-53	10	-141	-140	-73
Investing Cash Flow	17	-126	-17	94	-278	75	89	176	-58
Financing Cash Flow	0	103	102	0	340	3	12	0	78
Change in Cash	-35	-74	-15	-17	6	90	-42	37	-53

Global Institutional Holdings in Adaptimmune Therapeutics Plc

Funds	Holdings
EcoR1 Capital, LLC	10.34%
Long Focus Capital Management, LLC	8.96%
Two Seas Capital LP	7.75%
NEA Management Company, LLC	6.44%
Mpm Asset Management, LLC	2.01%

See all

Insights on Adaptimmune Therapeutics Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 3.22M → 13.67M (in $), with an average increase of 51.3% per quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, ADAP stock has moved up by 31.8%
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -74.21M → -30.34M (in $), with an average increase of 56.4% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 220.0%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 170.6%

About Adaptimmune Therapeutics Plc

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Organisation	Adaptimmune Therapeutics Plc
Headquarters	60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Industry	Health Technology
CEO	Mr. Adrian G. Rawcliffe
E-voting on shares	Click here to vote

Key Management of Adaptimmune Therapeutics Plc

Name	Title
Mr. William C. A. Bertrand Jr., Esq., J.D.	COO & Chief Compliance Officer
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.	Co-Founder
Ms. Kerry Sharp	Senior VP & General Counsel
Ms. Dana Lynch	Senior Director of Corporate Communications
Mr. Dennis Williams Pharm.D.	Senior Vice President of Late Stage Development
Ms. Margaret Henry	Corporate Secretary
Ms. Kimberly Freeman	Vice President of Commercial Planning
Mr. Adrian G. Rawcliffe	CEO & Director
Dr. Juli P. Miller Ph.D.	VP of Corporate Affairs & Investor Relations
Mr. John Lunger	Chief Patient Supply Officer

FAQs

What is Adaptimmune Therapeutics Plc share price today?

Adaptimmune Therapeutics Plc share price today is $0.05 as on September 13, 2025 at 1:29 am IST at the close of the market. Adaptimmune Therapeutics Plc share today touched a day high of $0.06 and a low of $0.05.

What is the 52 week high and 52 week low for Adaptimmune Therapeutics Plc share?

Adaptimmune Therapeutics Plc share touched a 52 week high of $1.12 on September 16, 2024 and a 52 week low of $0.04 on September 8, 2025. Adaptimmune Therapeutics Plc stock price today i.e. September 13, 2025 at 1:29 am IST is closed at $0.05,which is 95.54% down from its 52 week high and 24.07% up from its 52 week low.

What is Adaptimmune Therapeutics Plc's market capitalisation today?

Adaptimmune Therapeutics Plc market capitalisation is $0.00T as on September 13, 2025 at 1:29 am IST.

How to invest in Adaptimmune Therapeutics Plc Stock (ADAP) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Adaptimmune Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Adaptimmune Therapeutics Plc Shares that will get you 30.0000 shares as per Adaptimmune Therapeutics Plc share price of $0.05 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Adaptimmune Therapeutics Plc Stock (ADAP) from India?

Indian investors can start investing in Adaptimmune Therapeutics Plc (ADAP) shares with as little as ₹88.27 or $1 (as of September 15, 2025 at 1:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Adaptimmune Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on September 15, 2025 at 1:40 pm IST). Based on Adaptimmune Therapeutics Plc share’s latest price of $0.05 as on September 13, 2025 at 1:29 am IST, you will get 200.0000 shares of Adaptimmune Therapeutics Plc. Learn more about fractional shares .

What are the returns that Adaptimmune Therapeutics Plc has given to Indian investors in the last 5 years?

Adaptimmune Therapeutics Plc stock has given -99.44% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?